BC Innovations | Jun 4, 2015
Translation in Brief

If it FtsZ

Taxis Pharmaceuticals Inc. has rescued a series of compounds in development limbo through a deal with Biota Pharmaceuticals Inc. (NASDAQ:BOTA), and used the molecules to create a preclinical first-in-class antibiotic that kills Gram-positive bacteria by...
BC Innovations | Apr 5, 2012
Cover Story

MRSA sensitivity training

Researchers at Merck & Co. Inc. have identified targets in methicillin-resistant Staphylococcus aureus that synergize with b-lactam antibiotic targets to restore antibiotic sensitivity. 1 The findings suggest it may now be possible to use combinations...
BioCentury | Apr 26, 2010
Finance

The bite of reform

The initial negative impact of healthcare reform on pharma and biotech P&Ls is becoming apparent midway through earnings season. Investors shaved almost $4 billion off the market cap of Gilead Sciences Inc. (NASDAQ:GILD) last week...
BioCentury | Dec 7, 2009
Strategy

Meeting the Biota Quota

Biota Holdings Ltd. 's acquisition of MaxThera Inc. and Prolysis Ltd. fills some holes in its pipeline, which should help it achieve its long-term goal of having two or three out-licensed, royalty-generating compounds on the...
BC Week In Review | Nov 16, 2009
Company News

Biota, MaxThera Inc., Prolysis deal

Biota acquired fellow infectious disease companies MaxThera and Prolysis. Prolysis shareholders will receive A$10.8 million ($10 million) in Biota stock, or a 2.2% stake in Biota, while MaxThera shareholders will receive $1.2 million in cash...
BioCentury | Nov 16, 2009
Finance

Ebb & Flow

Although the terms of the acquisition of BioTrove Inc. by Life Technologies Corp. (NASDAQ:LIFE) haven't been undisclosed, the transaction could result in a more than 10X return over the next 12 months, according to investor...
BC Extra | Nov 13, 2009
Company News

Biota acquires MaxThera, Prolysis

Biota Holdings Ltd. (ASX:BTA) acquired fellow infectious disease companies MaxThera Inc. (Boston, Mass.) and Prolysis Ltd. (Yarnton, U.K.). Prolysis shareholders will receive A$10.8 million ($10 million) in Biota stock, or a 2.2% stake in Biota,...
BC Innovations | Oct 9, 2008
Cover Story

Blocking Bacterial Division

Prolysis Ltd. has published in Science the first animal data on an inhibitor of the bacterial cell division protein FtsZ, showing that PC190723 has activity against Staphylococci, including methicillin- and multidrug-resistant Staphylococcus aureus . 1 Other...
BC Innovations | Oct 2, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Infectious disease Staphylococcus FtsZ Studies in cell culture and in mice identified methoxybenzamide analogs as FtsZ inhibitors that could be useful...
BC Week In Review | Jan 22, 2007
Company News

Prolysis, The Wellcome Trust infectious news

Prolysis received a £3.5 million ($6.9) award from the Wellcome Trust's Seeding Drug Discovery initiative to develop antibacterials against methicillin-resistant S. aureus (MRSA). The company's CDI-936 series of preclinical antibacterials inhibit the S. aureus FtsZ...
Items per page:
1 - 10 of 21
BC Innovations | Jun 4, 2015
Translation in Brief

If it FtsZ

Taxis Pharmaceuticals Inc. has rescued a series of compounds in development limbo through a deal with Biota Pharmaceuticals Inc. (NASDAQ:BOTA), and used the molecules to create a preclinical first-in-class antibiotic that kills Gram-positive bacteria by...
BC Innovations | Apr 5, 2012
Cover Story

MRSA sensitivity training

Researchers at Merck & Co. Inc. have identified targets in methicillin-resistant Staphylococcus aureus that synergize with b-lactam antibiotic targets to restore antibiotic sensitivity. 1 The findings suggest it may now be possible to use combinations...
BioCentury | Apr 26, 2010
Finance

The bite of reform

The initial negative impact of healthcare reform on pharma and biotech P&Ls is becoming apparent midway through earnings season. Investors shaved almost $4 billion off the market cap of Gilead Sciences Inc. (NASDAQ:GILD) last week...
BioCentury | Dec 7, 2009
Strategy

Meeting the Biota Quota

Biota Holdings Ltd. 's acquisition of MaxThera Inc. and Prolysis Ltd. fills some holes in its pipeline, which should help it achieve its long-term goal of having two or three out-licensed, royalty-generating compounds on the...
BC Week In Review | Nov 16, 2009
Company News

Biota, MaxThera Inc., Prolysis deal

Biota acquired fellow infectious disease companies MaxThera and Prolysis. Prolysis shareholders will receive A$10.8 million ($10 million) in Biota stock, or a 2.2% stake in Biota, while MaxThera shareholders will receive $1.2 million in cash...
BioCentury | Nov 16, 2009
Finance

Ebb & Flow

Although the terms of the acquisition of BioTrove Inc. by Life Technologies Corp. (NASDAQ:LIFE) haven't been undisclosed, the transaction could result in a more than 10X return over the next 12 months, according to investor...
BC Extra | Nov 13, 2009
Company News

Biota acquires MaxThera, Prolysis

Biota Holdings Ltd. (ASX:BTA) acquired fellow infectious disease companies MaxThera Inc. (Boston, Mass.) and Prolysis Ltd. (Yarnton, U.K.). Prolysis shareholders will receive A$10.8 million ($10 million) in Biota stock, or a 2.2% stake in Biota,...
BC Innovations | Oct 9, 2008
Cover Story

Blocking Bacterial Division

Prolysis Ltd. has published in Science the first animal data on an inhibitor of the bacterial cell division protein FtsZ, showing that PC190723 has activity against Staphylococci, including methicillin- and multidrug-resistant Staphylococcus aureus . 1 Other...
BC Innovations | Oct 2, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Infectious disease Staphylococcus FtsZ Studies in cell culture and in mice identified methoxybenzamide analogs as FtsZ inhibitors that could be useful...
BC Week In Review | Jan 22, 2007
Company News

Prolysis, The Wellcome Trust infectious news

Prolysis received a £3.5 million ($6.9) award from the Wellcome Trust's Seeding Drug Discovery initiative to develop antibacterials against methicillin-resistant S. aureus (MRSA). The company's CDI-936 series of preclinical antibacterials inhibit the S. aureus FtsZ...
Items per page:
1 - 10 of 21